Eli Lilly announced up to $4 billion in acquisitions targeting three vaccine developers focused on shingles, Epstein-Barr virus, and other pathogens, marking a meaningful pipeline diversification away from its GLP-1 core. The deal is modest relative to LLY's market cap but signals strategic optionality into vaccines — a market with durable, recurring demand — which could re-rate sentiment modestly higher if pipeline derisking lands well.